Trial Profile
Phase I Study of Intraperitoneal Recombinant Human Interleukin-12 (rhIL-12) in Patients With Peritoneal Carcinomatosis, Associated With Mullerian and Gastrointestinal Carcinomas
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Interleukin-12 (Primary)
- Indications Gastrointestinal cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 04 Aug 2010 Status changed from active,no longer to completed as reported by ClinicalTrials.gov record.
- 10 Sep 2005 New trial record.